Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W8XH
|
|||
| Former ID |
DNC002358
|
|||
| Drug Name |
PI-103
|
|||
| Synonyms |
PI-103; 371935-74-9; PI103; 3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol; UNII-YQX02F616F; PI 103; PIK-103; Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-; YQX02F616F; CHEBI:90524; AK163162; 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol; 3-(4-Morpholin-4-Ylpyrido[3',2':4,5]furo[3,2-D]pyrimidin-2-Yl)phenol; Phenol, 3-(4-(4-morpholinyl)pyrido(3',2':4,5)furo(3,2-d)pyrimidin-2-yl)-; 3-(4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Investigative | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16N4O3
|
|||
| Canonical SMILES |
C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O
|
|||
| InChI |
1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2
|
|||
| InChIKey |
TUVCWJQQGGETHL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 371935-74-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14851847, 24171563, 26746641, 26759370, 45631627, 50100110, 53799218, 53800591, 56374189, 57373674, 71825407, 78998392, 92093191, 99302652, 99436951, 103694308, 103905507, 124659188, 124756953, 124898780, 124898781, 125163759, 125335464, 131465116, 134223008, 134964219, 135631956, 135685224, 135685225, 135685244, 136340108, 136367820, 136920407, 137275834, 141775457, 152258089, 160646928, 162011356, 162037397, 162169833, 162202614, 163125995, 163687483, 163893470, 164045350, 170481595, 171062264, 172650032, 172914365, 174561060
|
|||
| ChEBI ID |
CHEBI:90524
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5701). | |||
| REF 2 | The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.